BR112018016651A2 - composições e métodos para tratamento de doença e distúrbios de sinusite - Google Patents

composições e métodos para tratamento de doença e distúrbios de sinusite

Info

Publication number
BR112018016651A2
BR112018016651A2 BR112018016651A BR112018016651A BR112018016651A2 BR 112018016651 A2 BR112018016651 A2 BR 112018016651A2 BR 112018016651 A BR112018016651 A BR 112018016651A BR 112018016651 A BR112018016651 A BR 112018016651A BR 112018016651 A2 BR112018016651 A2 BR 112018016651A2
Authority
BR
Brazil
Prior art keywords
methods
disorders
compositions
sinus disease
treating sinus
Prior art date
Application number
BR112018016651A
Other languages
English (en)
Inventor
Barbalatt Sam
Original Assignee
Ent Tech Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2016900553A external-priority patent/AU2016900553A0/en
Application filed by Ent Tech Pty Ltd filed Critical Ent Tech Pty Ltd
Publication of BR112018016651A2 publication Critical patent/BR112018016651A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/731—Carrageenans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

uma composição compreendendo capa-carragenano e uma solução carreadora, em que a solução carreadora é uma solução isotônica, e métodos de uso da mesma no tratamento de doenças ou condições das vias respiratórias superiores.
BR112018016651A 2016-02-17 2017-02-17 composições e métodos para tratamento de doença e distúrbios de sinusite BR112018016651A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2016900553A AU2016900553A0 (en) 2016-02-17 Compositions and Methods for the Treatment of Sinus Diseases and Disorders
PCT/AU2017/050144 WO2017139854A1 (en) 2016-02-17 2017-02-17 Compositions and methods for the treatment of sinus disease and disorders

Publications (1)

Publication Number Publication Date
BR112018016651A2 true BR112018016651A2 (pt) 2018-12-26

Family

ID=59624790

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018016651A BR112018016651A2 (pt) 2016-02-17 2017-02-17 composições e métodos para tratamento de doença e distúrbios de sinusite

Country Status (13)

Country Link
US (1) US11357791B2 (pt)
EP (1) EP3416655A4 (pt)
JP (1) JP2019505538A (pt)
KR (1) KR20180108811A (pt)
CN (1) CN108697731A (pt)
AU (1) AU2017220396B2 (pt)
BR (1) BR112018016651A2 (pt)
CA (1) CA3013942C (pt)
HK (1) HK1258884A1 (pt)
IL (1) IL261134B2 (pt)
SG (1) SG11201806835SA (pt)
WO (1) WO2017139854A1 (pt)
ZA (1) ZA201806103B (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201806835SA (en) 2016-02-17 2018-09-27 Ent Tech Pty Ltd Compositions and methods for the treatment of sinus disease and disorders

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3563194B2 (ja) * 1996-03-15 2004-09-08 株式会社ノエビア 塩化ナトリウム含有ゲル組成物及びその製造方法
JPH11189533A (ja) * 1997-12-25 1999-07-13 Taisho Pharmaceut Co Ltd 点眼薬
US6214376B1 (en) * 1998-08-25 2001-04-10 Banner Pharmacaps, Inc. Non-gelatin substitutes for oral delivery capsules, their composition and process of manufacture
US6518244B2 (en) * 2000-03-09 2003-02-11 Intimax Corporation Combinations of heparin cofactor II agonist and platelet IIb/IIIa antagonist, and uses thereof
JP2002302448A (ja) * 2001-04-02 2002-10-18 Shiseido Co Ltd 皮膚外用剤
CN1491724A (zh) * 2003-09-02 2004-04-28 无锡杰西医药科技有限公司 一种适用于青光眼治疗的成胶增稠用多糖系统
EP1930015A1 (en) 2006-12-05 2008-06-11 Marinomed Biotechnologie GmbH Use of carrageenan for treating rhinovirus infections
US20080317791A1 (en) 2007-06-25 2008-12-25 Cp Kelco U.S., Inc. Kappa Carrageenan
JP2011219412A (ja) * 2010-04-09 2011-11-04 Saisentan Igaku Kenkyusho:Kk 緑内障の視野改善治療薬
CA2852591C (en) 2011-02-02 2019-02-12 Ent Technologies Pty Ltd Vitamin d3 compositions and uses thereof for the treatment of nasal passages
WO2012126777A1 (en) 2011-03-18 2012-09-27 Marinomed Biotechnologie Gmbh Inhibition of neuraminidase activity
AU2014215459A1 (en) 2013-02-05 2015-09-17 The Population Council, Inc. Intravaginal ring for the delivery of unique combinations of antimicrobial compositions
US10485819B2 (en) * 2013-12-03 2019-11-26 Gerolymatos International S.A. Ionic aqueous polysaccharide compositions
EP3099292A1 (en) * 2014-01-28 2016-12-07 Resdevco Research and Development Co. Ltd. Composition comprising xylitol and cholecalciferol for topical treatment of skin and mucous membranes
DE102015110674A1 (de) 2015-07-02 2017-01-05 Sms Group Gmbh Umbausystem für einen Elektrolichtbogenofen (EAF)
HUE062108T2 (hu) * 2015-07-14 2023-09-28 Marinomed Biotech Ag Vírusellenes hatású, orrdugulást megszûntetõ készítmény
SG11201806835SA (en) 2016-02-17 2018-09-27 Ent Tech Pty Ltd Compositions and methods for the treatment of sinus disease and disorders

Also Published As

Publication number Publication date
AU2017220396A1 (en) 2018-10-04
CA3013942C (en) 2024-03-26
WO2017139854A1 (en) 2017-08-24
US11357791B2 (en) 2022-06-14
EP3416655A1 (en) 2018-12-26
KR20180108811A (ko) 2018-10-04
IL261134B2 (en) 2023-03-01
US20200276226A1 (en) 2020-09-03
CN108697731A (zh) 2018-10-23
CA3013942A1 (en) 2017-08-24
SG11201806835SA (en) 2018-09-27
IL261134A (en) 2018-10-31
IL261134B (en) 2022-11-01
HK1258884A1 (zh) 2019-11-22
EP3416655A4 (en) 2019-11-20
ZA201806103B (en) 2019-07-31
JP2019505538A (ja) 2019-02-28
AU2017220396B2 (en) 2022-12-15

Similar Documents

Publication Publication Date Title
BR112015023349A2 (pt) composto, composição farmacêutica, e, método de tratamento de uma doença, condição de saúde ou distúrbio
NI201600164A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7
BR112017007975A2 (pt) composições e métodos para o tratamento de disfunção das glândulas meibomianas
BR112018004620A2 (pt) moduladores da expressão de kras
DOP2017000025A (es) Composiciones y métodos de uso para tratar trastornos metabólicos
DOP2017000268A (es) Metodos y kits para tratar depresion
BR112017009497A2 (pt) polinucleotídeos de aadc para o tratamento da doença de parkinson
BR112014021104A2 (pt) métodos e composições para o tratamento da doença de huntington
EA201691872A1 (ru) Гетероциклические соединения для применения в лечении pi3k-гамма-опосредованных расстройств
BR112015009948A2 (pt) antagonistas de ativina-actriia e usos para tratamento ósseos e outros disturbios
BR112018008601A2 (pt) composições compreendendo o canabidiol e segundos agentes terapêuticos para o tratamento de câncer
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
BR112017018964A2 (pt) uso de plinabulin e métodos para tratar tumor cerebral
CL2016001076A1 (es) (aza) piridopirazolopirimidinonas e indazolopirimidinonas como inhibidores de fibrinolosis.
BR112018001853A2 (pt) métodos para tratamento de um distúrbio e para melhoria do tratamento de um distúrbio
BR112017002526A2 (pt) terapia adjuvante com 25-hidroxivitamina d
CL2019001214A1 (es) Composición farmacéutica, métodos para tratamiento y sus usos.
AR096893A1 (es) Composición de un antagonista del factor de crecimiento del endotelio vascular (vegf, por sus siglas en inglés) para tratamiento de retinoterapia del prematuro
AR099707A1 (es) Composiciones y métodos para tratar trastornos renales
BR112015032343A8 (pt) uso de ligantes receptores sigma para a prevenção e tratamento de dor associada a cistite intersticial/síndrome de dor na bexiga (ic/bps)
BR112019003533A2 (pt) terapia de combinação com inibidores de glutaminase
MX2017014095A (es) Uso de cd24 para disminuir los niveles de colesterol de las lipoproteinas de baja densidad.
BR112016015997A2 (pt) ?composições farmacêuticas que compreendem 15- hepe e métodos para tratar asma e distúrbios pulmonares com o uso das mesmas?
BR112017003334A8 (pt) Variantes de desintegrina e usos farmacêuticos destas
BR112016024488A2 (pt) compostos de ciclo-hexenila, composições que compreendem esses e o uso dos mesmos

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI N? 10196/2001, QUE MODIFICOU A LEI N? 9279/96, A CONCESS?O DA PATENTE EST? CONDICIONADA ? ANU?NCIA PR?VIA DA ANVISA. CONSIDERANDO A APROVA??O DOS TERMOS DO PARECER N? 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL N? 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVID?NCIAS CAB?VEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2631 DE 08/06/2021 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements